14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ACHV vs NRIX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Achieve Life Sciences, Inc. (ACHV) captures the overall head-to-head institutional edge over Nurix Therapeutics, Inc. (NRIX) on higher Unified Composite conviction (56.6/100 HOLD vs. 52.9/100 HOLD) after splitting the core matrix 4–6 (led by Valuation Multiples, Options & Positioning), while NRIX wins 4–2 across the 6-pillar growth and valuation breakdown. ACHV trades at $6.78 (35.3x Forward P/E, 0.0% operating margin) versus NRIX at $14.87 (N/M Forward P/E, 41.3% operating margin).
Growth vs. Quality Trade-Off: ACHV earns the overall head-to-head edge with a stronger Unified Composite Score (56.6/100 HOLD vs. NRIX 52.9/100 HOLD) and 1.73β · 62% Vol risk profile, whereas NRIX leads top-line expansion (+8426.3% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: ACHV trades in a Neutral technical trend (BREAKOUT options phase, RSI 48.1); meanwhile NRIX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACHV vs NRIX. Trailing 12-month operating profitability (ACHV 0.0% vs NRIX 41.3%) and valuation multiples (ACHV 35.3x vs NRIX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $692.8M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
NRIX Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and 41.3% operating margin.
OpEx & R&D Reinvestment11.1% of Rev ($78M)
90D Engineering Disclosures0 Published
Investor FAQ ACHV vs NRIX Key Questions & Quantitative Answers
As of Nov 16, 2026, Achieve Life Sciences, Inc. (ACHV) captures the overall head-to-head institutional edge over Nurix Therapeutics, Inc. (NRIX) on higher Unified Composite conviction (56.6/100 HOLD vs. 52.9/100 HOLD) after splitting the core matrix 4–6 (led by Valuation Multiples, Options & Positioning), while NRIX wins 4–2 across the 6-pillar growth and valuation breakdown. ACHV trades at $6.78 (35.3x Forward P/E, 0.0% operating margin) versus NRIX at $14.87 (N/M Forward P/E, 41.3% operating margin). Growth vs. Quality Trade-Off: ACHV earns the overall head-to-head edge with a stronger Unified Composite Score (56.6/100 HOLD vs. NRIX 52.9/100 HOLD) and 1.73β · 62% Vol risk profile, whereas NRIX leads top-line expansion (+8426.3% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ACHV trades in a Neutral technical trend (BREAKOUT options phase, RSI 48.1); meanwhile NRIX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NRIX leads the Growth & Scale pillar: ACHV posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NRIX at +8426.3% YoY revenue growth and +0.0% YoY earnings growth on $702M TTM revenue (52.4% gross margin, 41.3% operating margin). On trailing 12-month operating scale, ACHV generates N/A in USD-normalized revenue versus $702M for NRIX. In operating R&D and SG&A reinvestment, ACHV deploys N/A (0 90-day corporate R&D disclosures) versus 11.1% of Rev ($78M) (0 disclosures) for NRIX.
ACHV screens cheaper on headline valuation multiples. ACHV trades at 35.3x Forward P/E, 35.3x Trailing P/E, 17.68x PEG, and N/M EV/Revenue (unreported FCF margin), whereas NRIX trades at N/M Forward P/E, 6.4x Trailing P/E, N/M PEG, and 1.5x EV/Revenue (52.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACHV (-845.0% ROE) versus NRIX (44.0% ROE) capital efficiency.
In options market volatility and institutional positioning, ACHV carries 88.3% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.73β · 62% Vol realized risk). By comparison, NRIX carries 79.8% implied volatility (4th %ile, Compressed (<25th %ile)), a 3.05x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.94β · 141% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.